Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus.

Kato Y, Park J, Takamatsu H, Konaka H, Aoki W, Aburaya S, Ueda M, Nishide M, Koyama S, Hayama Y, Kinehara Y, Hirano T, Shima Y, Narazaki M, Kumanogoh A.

Ann Rheum Dis. 2018 Oct;77(10):1507-1515. doi: 10.1136/annrheumdis-2018-212988. Epub 2018 Jun 26.

2.

Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus.

Sakakibara S, Arimori T, Yamashita K, Jinzai H, Motooka D, Nakamura S, Li S, Takeda K, Katayama J, El Hussien MA, Narazaki M, Tanaka T, Standley DM, Takagi J, Kikutani H.

Sci Rep. 2017 Nov 27;7(1):16428. doi: 10.1038/s41598-017-16681-y.

3.

Interleukin (IL-6) Immunotherapy.

Tanaka T, Narazaki M, Kishimoto T.

Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8). pii: a028456. doi: 10.1101/cshperspect.a028456. Review.

PMID:
28778870
4.

The role and therapeutic targeting of IL-6 in rheumatoid arthritis.

Narazaki M, Tanaka T, Kishimoto T.

Expert Rev Clin Immunol. 2017 Jun;13(6):535-551. doi: 10.1080/1744666X.2017.1295850. Epub 2017 Mar 3. Review.

PMID:
28494214
5.

Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis.

Nishide M, Nojima S, Ito D, Takamatsu H, Koyama S, Kang S, Kimura T, Morimoto K, Hosokawa T, Hayama Y, Kinehara Y, Kato Y, Nakatani T, Nakanishi Y, Tsuda T, Park JH, Hirano T, Shima Y, Narazaki M, Morii E, Kumanogoh A.

Ann Rheum Dis. 2017 Aug;76(8):1440-1448. doi: 10.1136/annrheumdis-2016-210706. Epub 2017 Apr 17.

6.

Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese Individuals.

Motooka D, Fujimoto K, Tanaka R, Yaguchi T, Gotoh K, Maeda Y, Furuta Y, Kurakawa T, Goto N, Yasunaga T, Narazaki M, Kumanogoh A, Horii T, Iida T, Takeda K, Nakamura S.

Front Microbiol. 2017 Feb 15;8:238. doi: 10.3389/fmicb.2017.00238. eCollection 2017.

7.

Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine.

Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K, Hirota K, Matsushita M, Furuta Y, Narazaki M, Sakaguchi N, Kayama H, Nakamura S, Iida T, Saeki Y, Kumanogoh A, Sakaguchi S, Takeda K.

Arthritis Rheumatol. 2016 Nov;68(11):2646-2661. doi: 10.1002/art.39783.

8.

Regulation of IL-6 in Immunity and Diseases.

Tanaka T, Narazaki M, Masuda K, Kishimoto T.

Adv Exp Med Biol. 2016;941:79-88.

PMID:
27734409
9.

Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186.

Fujimoto K, Kinoshita M, Tanaka H, Okuzaki D, Shimada Y, Kayama H, Okumura R, Furuta Y, Narazaki M, Tamura A, Hatakeyama S, Ikawa M, Tsuchiya K, Watanabe M, Kumanogoh A, Tsukita S, Takeda K.

Mucosal Immunol. 2017 Mar;10(2):446-459. doi: 10.1038/mi.2016.58. Epub 2016 Jul 6.

PMID:
27381925
10.

Immunotherapeutic implications of IL-6 blockade for cytokine storm.

Tanaka T, Narazaki M, Kishimoto T.

Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020. Review.

PMID:
27381687
11.

LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-κB activation.

Morimoto K, Baba Y, Shinohara H, Kang S, Nojima S, Kimura T, Ito D, Yoshida Y, Maeda Y, Sarashina-Kida H, Nishide M, Hosokawa T, Kato Y, Hayama Y, Kinehara Y, Okuno T, Takamatsu H, Hirano T, Shima Y, Narazaki M, Kurosaki T, Toyofuku T, Kumanogoh A.

Sci Rep. 2016 May 11;6:25738. doi: 10.1038/srep25738.

12.

Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis.

Ohmi Y, Ise W, Harazono A, Takakura D, Fukuyama H, Baba Y, Narazaki M, Shoda H, Takahashi N, Ohkawa Y, Ji S, Sugiyama F, Fujio K, Kumanogoh A, Yamamoto K, Kawasaki N, Kurosaki T, Takahashi Y, Furukawa K.

Nat Commun. 2016 Apr 5;7:11205. doi: 10.1038/ncomms11205.

13.

Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications.

Yoshida Y, Ogata A, Kang S, Ebina K, Shi K, Nojima S, Kimura T, Ito D, Morimoto K, Nishide M, Hosokawa T, Hirano T, Shima Y, Narazaki M, Tsuboi H, Saeki Y, Tomita T, Tanaka T, Kumanogoh A.

Arthritis Rheumatol. 2015 Jun;67(6):1481-90. doi: 10.1002/art.39086.

14.

IL-6 in inflammation, immunity, and disease.

Tanaka T, Narazaki M, Kishimoto T.

Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. doi: 10.1101/cshperspect.a016295. Review.

15.

A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.

Tanaka T, Narazaki M, Ogata A, Kishimoto T.

Semin Immunol. 2014 Feb;26(1):88-96. doi: 10.1016/j.smim.2014.01.009. Epub 2014 Mar 1. Review.

PMID:
24594001
16.

Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.

Shima Y, Hosen N, Hirano T, Arimitsu J, Nishida S, Hagihara K, Narazaki M, Ogata A, Tanaka T, Kishimoto T, Kumanogoh A.

Mod Rheumatol. 2015 Jan;25(1):134-7. doi: 10.3109/14397595.2013.874749. Epub 2014 Feb 18.

PMID:
24533556
17.

Immune reconstitution inflammatory syndrome in a patient with adult-onset Still's disease: graft-versus-host-like skin reaction with possible asymptomatic human herpes virus reactivation during steroid tapering.

Yamaga K, Hanafusa T, Azukizawa H, Tanemura A, Nii T, Nishide M, Narazaki M, Katayama I.

Eur J Dermatol. 2014 Jan-Feb;24(1):101-3. doi: 10.1684/ejd.2013.2218. No abstract available.

PMID:
24334185
18.

Therapeutic targeting of the interleukin-6 receptor.

Tanaka T, Narazaki M, Kishimoto T.

Annu Rev Pharmacol Toxicol. 2012;52:199-219. doi: 10.1146/annurev-pharmtox-010611-134715. Epub 2011 Sep 9. Review.

PMID:
21910626
19.

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T.

Mod Rheumatol. 2012 Apr;22(2):298-302. doi: 10.1007/s10165-011-0497-5. Epub 2011 Jul 12.

PMID:
21748365
20.

Therapeutic effect of tocilizumab on two patients with polymyositis.

Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T.

Rheumatology (Oxford). 2011 Jul;50(7):1344-6. doi: 10.1093/rheumatology/ker152. Epub 2011 Apr 22. No abstract available.

PMID:
21515628

Supplemental Content

Loading ...
Support Center